<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002079</url>
  </required_header>
  <id_info>
    <org_study_id>057B</org_study_id>
    <secondary_id>NS8-91-02-009</secondary_id>
    <nct_id>NCT00002079</nct_id>
  </id_info>
  <brief_title>Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)</brief_title>
  <official_title>Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G D Searle</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered in&#xD;
      combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3. To&#xD;
      determine the safety of escalating doses of SC-48334 when administered in combination with&#xD;
      any of three doses of AZT to symptomatic HIV-1 positive patients with 200 - 500 CD4+&#xD;
      cells/mm3, and to assess the pharmacokinetics of the two drugs, given separately and in&#xD;
      combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Butyldeoxynojirimycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 cell count 200 - 500 cells/mm3.&#xD;
&#xD;
          -  Prior therapy with 12 - 48 weeks of AZT.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Clinically significant diarrhea without definable cause (&gt; 3 liquid stools per day for&#xD;
             more than 7 days within 6 months prior to study entry).&#xD;
&#xD;
          -  Diarrhea, as above, with known non-HIV-related cause occurring within 1 month prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Symptoms meeting CDC criteria for AIDS classification.&#xD;
&#xD;
          -  Fever as a constitutional sign of HIV disease (&gt; 38.5 degrees C persisting for more&#xD;
             than 14 consecutive days or for more than 15 days in any given 30-day period prior to&#xD;
             study entry).&#xD;
&#xD;
          -  Malignancies, other than basal cell carcinoma and Kaposi's sarcoma (provided patient&#xD;
             has fewer than 10 Kaposi's sarcoma lesions, no non-skin lesions, and no requirement&#xD;
             for systemic treatment).&#xD;
&#xD;
          -  Significant organ dysfunction.&#xD;
&#xD;
          -  Known hypersensitivity to SC-48334 or AZT or related compounds.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any investigational drug other than SC-48334.&#xD;
&#xD;
          -  Any anti-HIV drug other than AZT.&#xD;
&#xD;
          -  Cancer chemotherapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of cataracts or known increased risk of cataract formation.&#xD;
&#xD;
          -  Known hypersensitivity to SC-48334 or AZT or related compounds.&#xD;
&#xD;
          -  History of lactose intolerance.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior SC-48334.&#xD;
&#xD;
          -  Cancer chemotherapy within 6 months prior to study entry.&#xD;
&#xD;
          -  Treatment with any investigational drug or any drug with anti-HIV activity, other than&#xD;
             AZT, within 30 days prior to study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Whole-body irradiation within 6 months prior to study entry. Current use of illicit&#xD;
        substances, or abuse of alcohol, which would limit compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr Marcus Conant</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shared Med Research Foundation</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratogen of South Florida</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hosp / Infectious Disease Rsch Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Paces Clinical Research Incoporated</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Samuel W Golden</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas Veterans Administration Med Ctr</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Daniel Barbero</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Plaza Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):139-47.</citation>
    <PMID>7905523</PMID>
  </reference>
  <verification_date>March 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Zidovudine</keyword>
  <keyword>1-Deoxynojirimycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

